Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis.

Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis.
复制标题

DOI:
10.1126/sciadv.add8693
复制
发表时间:
2023-06-02
期刊:
影响因子:
13.6
通讯作者:
--
中科院分区:
综合性期刊1区
文献类型:
--
作者:

文献摘要

参考文献

相似文献

多发性硬化症(MS)是一种自身免疫性疾病,其特征是自身反应性免疫细胞损害有髓鞘神经,损害脑功能。治疗的目的是诱导耐受性,以重新教育免疫系统将髓磷脂识别为“自身”而不是“外来”。由于外周免疫耐受主要由调节性T细胞(Treg)介导,我们开发了一种支持Treg体内扩增和活性的疗法。为了靶向、接合和激活髓磷脂特异性Tcl 3,我们设计了一种可生物降解的微粒(MP),其装载有雷帕霉素,并用偏向的白细胞介素-2(IL-2)融合蛋白和装载有髓磷脂肽的主要组织相容性复合物(MHC)II类进行功能化。这些致耐受性MP(Tol-MP)在体外进行了验证,然后在MS,实验性自身免疫性脑脊髓炎(EAE)的小鼠模型中进行了评价。Tol-MPs促进了100%小鼠的持续疾病逆转,并使38%具有症状性EAE的小鼠完全恢复。Tol-MPs是治疗自身免疫性疾病的有前途的平台。生物工程致耐受性颗粒逆转多发性硬化症小鼠模型中的疾病。
Multiple sclerosis (MS) is an autoimmune disease characterized by autoreactive immune cells damaging myelinated nerves, impairing brain function. Treatments aim for tolerance induction to reeducate the immune system to recognize myelin as “self” rather than “foreign.” As peripheral immune tolerance is primarily mediated by regulatory T cells (Tregs), we developed a therapy to support Treg expansion and activity in vivo. To target, engage, and activate myelin-specific Tregs, we designed a biodegradable microparticle (MP) loaded with rapamycin and functionalized with a biased interleukin-2 (IL-2) fusion protein and a major histocompatibility complex (MHC) class II loaded with a myelin peptide. These tolerogenic MPs (Tol-MPs) were validated in vitro and then evaluated in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE). Tol-MPs promoted sustained disease reversal in 100% of mice and full recovery in 38% of mice with symptomatic EAE. Tol-MPs are a promising platform for treatment of autoimmune diseases. Bioengineered tolerogenic particles reverse disease in a mouse model of multiple sclerosis.
DOI: 10.1016/j.clim.2015.04.013
发表时间: 2015-09
期刊: Clinical immunology (Orlando, Fla.)
影响因子: --
作者:
Fisher JD;Acharya AP;Little SR
通讯作者: Little SR
DOI: 10.1016/j.clim.2015.03.023
发表时间: 2015-09
期刊: Clinical immunology (Orlando, Fla.)
影响因子: --
作者:
Lewis JS;Dolgova NV;Zhang Y;Xia CQ;Wasserfall CH;Atkinson MA;Clare-Salzler MJ;Keselowsky BG
通讯作者: Keselowsky BG
DOI: 10.1021/nn405033r
发表时间: 2014-03-25
期刊: ACS nano
影响因子: 17.1
作者:
Hunter Z;McCarthy DP;Yap WT;Harp CT;Getts DR;Shea LD;Miller SD
通讯作者: Miller SD
DOI: 10.1073/pnas.1408686111
发表时间: 2015-01-13
影响因子: 11.1
作者:
Maldonado, Roberto A.;LaMothe, Robert A.;Kishimoto, Takashi Kei
通讯作者: Kishimoto, Takashi Kei
DOI: 10.1016/j.biomaterials.2017.07.029
发表时间: 2017-10
期刊: Biomaterials
影响因子: 14
作者:
Cho JJ;Stewart JM;Drashansky TT;Brusko MA;Zuniga AN;Lorentsen KJ;Keselowsky BG;Avram D
通讯作者: Avram D